Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients  Bram L.T.

Published byRoss Murphy Modified over 6 years ago

Similar presentations

Presentation on theme: "Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients  Bram L.T."— Presentation transcript:

1 Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients  Bram L.T. Ramaekers, MSc, Manuela A. Joore, PhD, Béranger Lueza, MSc, Julia Bonastre, PhD, Audrey Mauguen, MSc, Jean-Pierre Pignon, MD, PhD, Cecile Le Pechoux, MD, Dirk K.M. De Ruysscher, MD, PhD, Janneke P.C. Grutters, PhD  Journal of Thoracic Oncology  Volume 8, Issue 10, Pages (October 2013) DOI: /JTO.0b013e31829f6c55 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Diagrammatical representation of the Markov model structure. *The numbers (1 and 2) next to the arrows correspond to the Weibull models in Appendix 2 (Supplemental Digital Content 1, †Acute toxicity included grade 3 or higher pulmonary toxicity, esophageal toxicity, and hematological toxicity (see Appendix 3 [Supplemental Digital Content 1, for the corresponding logistic regression models). ‡Late toxicity included grade 3 or higher pulmonary toxicity and esophageal toxicity (Table 1). §Noncancer mortality was defined as deaths resulting from causes other than cancer and not occurring after disease progression. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Cost effectiveness acceptability curves. The vertical line represents the ceiling ratio that was adopted in our analyses (€80,000 per QALY gained). CRT, conventional fractionation radiotherapy; VART, very accelerated radiotherapy; MART, moderately accelerated radiotherapy; HRT, hyperfractionated radiotherapy. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Expected value of individualized care and expected value of perfect information. The vertical line represents the ceiling ratio that was adopted in our analyses (€80,000 per quality-adjusted life year gained). Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 10 trials (N = 2000) Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

6 HRTH versus CRT Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

7 HRTI versus CRT Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

8 VART versus CRT Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

9 MART Versus CRT Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

10 VART versus HRTI Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

11 MART versus VART Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31829f6c55) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients  Bram L.T."

Similar presentations

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 
Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Volume 14, Issue 7, Pages (June 2013)

Volume 14, Issue 7, Pages (June 2013)

Similar presentations

Ads by Google